Medical imaging is a key component in the clinical management of cancer patients. Cancer imaging agents are used in conjunction with medical imaging equipment and, by highlighting the contrast between normal and malignant tissues, allow the collection of information on cancer presence and progression. Developing novel imaging agents that can be used for imaging and targeted radiotherapy of cancer would greatly enhance the efficacy of the cancer patient management and help usher in a new era of personalized cancer therapy.
According to market research firm Markets and Markets, the global diagnostic imaging market, which stood at
In Phase 1, Rockland and Abzyme Therapeutics will develop, label, and characterize high-affinity single domain antibodies (sdAbs) against EGFR, Her2 and Mesothelin. Under the terms of this grant, Abzyme Therapeutics will develop single domain antibodies and Rockland will be responsible for bioconjugation and in vivo characterization.
“Despite significant scientific progress, very few cancer imaging agents are available in the clinic,” commented Carl A Ascoli, PhD, Laboratory Director at Rockland Immunochemicals. “The size, ease of manufacture, and condition-resistant nature of sdAbs make them the best choice as capture molecules. We expect that our sdAb imaging agents will have superiority over other agents designed for in vivo and in situ biodetection and diagnosis.”
“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop and commercialize technologies that will ultimately benefit humanity,” continued
In the planned Phase II portion of this project, the key antibodies will be radionuclide labeled and characterized using PET scanners in collaboration with
About Rockland Immunochemicals
Rockland Immunochemicals has supported the academic, biopharma and diagnostic industries with antibodies and antibody based tools™ for basic research, assay development and preclinical studies for over 50 years. With facilities in
Read the full story at http://www.prweb.com/releases/2013/10/prweb11271069.htm
Most Popular Stories
- Twitter Names Woman to Board
- Obamacare Doing Just Fine, Ky. Governor Says
- Rand Paul Signs up for Obamacare
- Hispanic Employment Improves in November
- Aspen Contracting Adding 300 Jobs
- Trapped Florida Whales Head for Deeper Waters
- U.S. Chamber to Run Ads in Idaho, W.Va.
- Thalia Gets Star on Hollywood Walk of Fame
- U.S. Unemployment Rate Dips to 7 Percent
- American Eagle Issues Weak Q4 Outlook